Jason Starr, DO, discusses the importance of molecular residual disease within the cancer treatment landscape.
EP. 1: Explaining Molecular Residual Disease
Jason Starr, DO, provides an overview of molecular residual disease (MRD) in the hematological and oncological treatment landscapes.
EP. 2: The Evolution of Circulating Tumor DNA in Oncology
Jason Starr, DO, explains circulating tumor DNA’s (ctDNA) role in oncology and its role in MRD.
EP. 3: MRD Assessments
Jason Starr, DO, discusses MRD assessments, including: when they are done, where the testing takes place, and how often they are recommended.
EP. 4: MRD Results and Guiding Treatment Decisions
Kashyap Patel, MD, and Jason Starr, DO, explain the various potential uses for MRD results and how they guide treatment decisions.
EP. 5: MRD and Value-Based Care Models
Dr Patel describes the importance of MRD in value-based care models.
EP. 6: Supporting MRD Availability
Our experts tell us how we can support the availability of MRD for more patients.
EP. 7: INSPIRE and IMvigor011 Trials
Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.
EP. 8: Potential Changes for MRD in the Future
Kashyap Patel, MD, and Jason Starr, DO, explain the potential changes providers might see in the future for MRD.
2 Clarke Drive Cranbury, NJ 08512